Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Vignesh Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | March 22, 2023
Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel.
Read More
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | February 27, 2023
IFNα and nadofaragene firadenovec can provide a new therapy approach for a disease with a significant unmet clinical need.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | February 24, 2023
BCG plus nogapendekin alfa inbakicept may offer an enhanced treatment option for patients with high-risk NMIBC.
Andrea Necchi, MDASCO GU Symposium 2023 | February 18, 2023
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
Kyle M. Rose, MDASCO GU Symposium 2023 | February 18, 2023
Kyle M. Rose, MD, describes how cell-free DNA is used to detect MRD prior to repeat-transurethral resection in NMIBC.
Emily MenendezASCO GU Symposium 2023 | February 17, 2023
A recent study analyzed the effectiveness of BCG treatment in patients with NMIBC, including a subgroup of patients with CIS.
Joshua Meeks, MD, PhDNon-Muscle Invasive Urothelial Carcinoma | January 27, 2023
Joshua Meeks, MD, PhD, discusses ongoing research in NMIBC and the future of urothelial carcinoma care.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | January 25, 2023
Researchers developed a randomized phase II clinical trial for patients with NMIBC before transurethral resection of tumors.
Colin Dinney, MDExpert Interviews | January 5, 2023
Colin Dinney, MD, explains the data that led to FDA approval of Adstiladrin for NMIBC and how it impacts the treatment.
David Ambinder, MDJournal | December 19, 2022
By administering immediate single-dose intravesical chemotherapy, there is a 15% absolute risk reduction in tumor recurrence.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | December 19, 2022
The FDA approved Adstiladrin, a gene therapy for the treatment of adult patients with high-risk BCG-unresponsive NMIBC.
Leah LawrenceNon-Muscle Invasive Urothelial Carcinoma | December 13, 2022
Endoscopic balloon cryoablation is an effective therapy for transurethral resection of non-muscle invasive bladder cancer.
David Ambinder, MDJournal | November 22, 2022
The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes.
David Ambinder, MDJournal | November 22, 2022
A study analyzing the safety and efficacy of large surface area microparticle docetaxel for NMIBC is reviewed.
David Ambinder, MDJournal | October 24, 2022
Researchers evaluated the safety and efficacy of intravesical pembrolizumab when in conjunction with intravesical BCG.
Leah LawrenceNon-Muscle Invasive Urothelial Carcinoma | October 18, 2022
Short-term intensive chemoresection, a nonsurgical treatment modality, treated recurrent NMIBC, reducing required procedures.
Cecilia BrownNon-Muscle Invasive Urothelial Carcinoma | August 8, 2022
The induction lymphocyte-to-monocyte ratio was associated with “better accuracy” and than the preoperative ratio.
Cecilia BrownNon-Muscle Invasive Urothelial Carcinoma | July 29, 2022
While BCG has been the standard adjuvant therapy for patients with high-risk NMIBC, a shortage has led to other regimens.
David Ambinder, MDJournal | July 27, 2022
The current standard of care for patients with high-grade NMIBC, intravesical Bacillus Calmette-Guérin, is discussed.
Cecilia BrownNon-Muscle Invasive Urothelial Carcinoma | July 26, 2022
Pathogenic variants were more common in patients who had high-grade NMIBC than in patients with low-grade NMIBC.
Advertisement
Advertisement
Advertisement